文献速递其他结缔组织病

系统性硬化相关间质性肺病在造血干细胞移植或环磷酰胺治疗一年后的演变

Evolution of Systemic Sclerosis-Associated Interstitial Lung Disease One Year After Hematopoietic Stem Cell Transplantation or Cyclophosphamide.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2022-01-13

本回顾性观察研究纳入51例系统性硬化相关间质性肺病(SSc-ILD)患者(HSCT组20例,CYC组31例),半定量评分基线与1年HRCT。HSCT组总ILD评分平均变化为-5.1%(95%CI -10.2, 0.0;P=0.050),CYC组为-1.0%(95%CI -4.3, 2.3;P=0.535)。HRCT评分变化与肺功能检查(PFT)结果的关联较弱。

要点

  • HSCT组1年ILD范围有非显著性但明确的减少(P=0.050)。
  • CYC组1年ILD评分变化无统计学意义(P=0.535)。
  • 基线较高GGO、较高总ILD和较低DLCO预测ILD改善,但多变量模型未建立。

核心结论

  • HSCT治疗后一年观察到SSc-ILD范围非显著性但明确的减少。
  • PFT结果变化与HRCT评分变化相关但相关性弱,不能视为 conclusive。

研究设计与样本

  • 回顾性观察研究,纳入51例SSc-ILD患者,HSCT组20例,CYC组31例。
  • 对基线和1年HRCT半定量评分总ILD范围、网状影和磨玻璃影(GGO)。

主要发现

  • HSCT组总ILD评分平均变化-5.1%(95%CI -10.2, 0.0;P=0.050)。
  • CYC组总ILD评分平均变化-1.0%(95%CI -4.3, 2.3;P=0.535)。
  • 所有患者中HRCT评分演变与PFT结果相对变化弱相关。
  • 单变量logistic回归中,基线较高GGO、较高总ILD和较低DLCO预测ILD范围改善。

关键数值与推荐

  • HSCT组总ILD评分平均变化-5.1%(95%CI -10.2, 0.0;P=0.050)。
  • CYC组总ILD评分平均变化-1.0%(95%CI -4.3, 2.3;P=0.535)。

临床怎么用

  • 对于进展性SSc-ILD,HSCT可能使1年ILD范围减少,但需注意统计显著性边缘。
  • PFT变化与HRCT变化相关性弱,解读时需结合影像学。
  • 基线GGO、总ILD和DLCO可能提示ILD改善概率,但多变量独立性未评估。

局限性

  • 回顾性观察研究,样本量较小(51例)。
  • 多变量模型未能建立以评估预测因素的独立性。
  • HRCT评分变化与PFT结果相关性弱,不能视为 conclusive。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hematopoietic stem cell transplantation (HSCT) and cyclophosphamide (CYC) are treatment options for progressive systemic sclerosis associated with interstitial lung disease (SSc-ILD). The aims of our retrospective observational study were to evaluate: 1) the evolution of SSc-ILD in SSc patients treated with HSCT (assessed by high-resolution computed tomography [HRCT]; a group of patients treated with CYC was included as frame of reference); 2) how results of pulmonary function tests (PFTs) are associated with HRCT findings; and 3) which factors predict ILD reduction. METHODS: We semiquantitatively scored total ILD extent, reticulations, and ground-glass opacities (GGO) scores at baseline and at the 1-year HRCTs of SSc patients treated with HSCT or CYC. Linear association between changes in HRCT scores and PFT results and predictors of ILD improvement were studied. RESULTS: We included 51 patients (those treated with HSCT [n = 20] and those treated with CYC [n = 31]). The mean change in total ILD score was -5.1% (95% confidence interval [95% CI] -10.2, 0.0) in the HSCT treatment group (P = 0.050), and -1.0% (95% CI -4.3, 2.3) in the CYC treatment group (P = 0.535). For all patients, the evolution of HRCT scores was weakly associated with relative changes in PFT results. In univariate logistic regression, higher ground-glass opacities, higher total ILD, and lower single-breath diffusing capacity for carbon monoxide scores at baseline predicted improvement of ILD extent after treatment, but a multivariable model could not be built to assess independency of predictors. CONCLUSION: One year after treatment with HSCT, a nonsignificant but clear reduction of SSc-ILD extent was observed. Changes in PFT results were associated with changes in HRCT scores but the correlation was weak and cannot be considered conclusive.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Ciaffi J, van Leeuwen NM, Boonstra M, et al. Evolution of Systemic Sclerosis-Associated Interstitial Lung Disease One Year After Hematopoietic Stem Cell Transplantation or Cyclophosphamide. Arthritis Care Res (Hoboken). 2022. PMID: 32961038. doi:10.1002/acr.24451

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。